Difference between revisions of "20.109(F20):Journal club presentation"

From Course Wiki
Jump to: navigation, search
Line 9: Line 9:
  
 
'''Malaria drug discovery'''
 
'''Malaria drug discovery'''
 +
 +
#Istvan ''et. al.'' "[[Media:Istvan Plasmodium Niemann-Pick type C1.pdf|''Plasmodium'' Niemann-Pick type C1-related protein is a druggable target reguired for parasite membrane homeostasis.]]" (2019) eLife. 8:e40529.
 +
  
 
Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830
 
Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830

Revision as of 23:56, 24 July 2020

20.109(F20): Laboratory Fundamentals of Biological Engineering

Fa20 banner image v2.png

Fall 2020 schedule        FYI        Assignments        Homework        Communication |        Accessibility

       M1: Genomic instability        M2: Drug discovery        M3: Metabolic engineering       


FIND ARTICLES FOR CATEGORIES: MALARIA BIOLOGY, SMM STUDIES, DRUG DISCOVERY RESEARCH

P. falciparum biology

Malaria drug discovery

  1. Istvan et. al. "Plasmodium Niemann-Pick type C1-related protein is a druggable target reguired for parasite membrane homeostasis." (2019) eLife. 8:e40529.


Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830
Retrieved from "http://measurebiology.org/w/index.php?title=20.109(F20):Journal_club_presentation&oldid=45150"